Decentralised trials (DCTs) or virtual trials are those that allow patients to participate in the studies without visiting the clinic site.
The use of DCTs soared following the COVID-19 pandemic after lockdowns were imposed and several restrictions were placed on movement.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData conducted a survey to assess pre-pandemic DCT use by company role.
Pre-pandemic Decentralised Trial Use by Company Role
The survey found that nearly half (49%) of other contract service providers started using DCTs before the COVID-19 pandemic. It includes CMOs, bioanalysis, training, consulting, software and digital solution providers for clinical trials.
The adoption rate of virtual trials before coronavirus stood at 42% and 36% for CROs and clinical/ investigator sites, respectively.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe survey also found that only 19% of Pharma/ Biotech and 14% of Government/ Academic Institutes explored DCTs before the pandemic hit the world.
The analysis is based on responses received from the GlobalData Coronavirus Survey -– Pharmaceutical Imports/Exports and Supply Chain, fielded between 04 June and 22 June 2020.
